Although deaths from cancer have gone down over the last couple decades, the disease remains one of the leading causes of death in the United States, just as it has for the last 75 years, according to ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

According to Medi-Tech Insights, the global Agentic AI in Healthcare market is poised for exceptional growth, projecting a ...

Mumbai: The Mumbai Crime Branch Unit 6 successfully traced and rescued a 3-year-old boy who was allegedly kidnapped from his ...

The global lipid nanoparticles (LNP) contract development and manufacturing organization (CDMO) market is poised for ...

Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus (EBV)-driven lymphomas. The findings, ...

Our large observational study adds long-term survival to the mounting data supporting the use and safety of conservative surgery for low-risk, early-stage cervical carcinoma,” the researchers wrote.

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Dymicron’s Triadyme-C artificial disc earned the FDA’s investigational device exemption approval, according to a July 10 news release. The IDE approval opens the door for a U.S. trial of the disc, ...

A test developed by a Madison company to better track cancer DNA in the blood stream will now be covered by Medicare.  Exact Sciences, which is headquartered in the UW Research Park and has labs along ...